Lynnette Fernandez-Cuesta

Lynnette Fernandez-Cuesta

UNVERIFIED PROFILE

Are you Lynnette Fernandez-Cuesta?   Register this Author

Register author
Lynnette Fernandez-Cuesta

Lynnette Fernandez-Cuesta

Publications by authors named "Lynnette Fernandez-Cuesta"

Are you Lynnette Fernandez-Cuesta?   Register this Author

24Publications

1255Reads

5Profile Views

New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management.

J Thorac Oncol 2018 06 14;13(6):752-766. Epub 2018 Feb 14.

Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, IARC-WHO, Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.02.002DOI Listing
June 2018

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.

Clin Cancer Res 2018 01 24;24(1):33-42. Epub 2017 Oct 24.

Department of Pulmonary Diseases, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-1921DOI Listing
January 2018

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.

J Thorac Oncol 2017 04 27;12(4):724-733. Epub 2016 Dec 27.

Faculty of Medicine, Research Team 3738, Lyon1 University, Oullins, France; French National Network for the Treatment of Rare Peritoneal Surface Malignancies, University Hospital of Lyon and Lyon1 University, Lyon, France; Department of Pathology, University Hospital of Lyon and Lyon1 University, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.12.019DOI Listing
April 2017

Genomic architecture of lung cancers.

Curr Opin Oncol 2016 Jan;28(1):52-7

Group of Genetic Cancer Susceptibility, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), Lyon, France.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-oncology/9000/00000/Genomic_
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CCO.0000000000000251DOI Listing
January 2016

Comprehensive genomic profiles of small cell lung cancer.

Nature 2015 Aug 13;524(7563):47-53. Epub 2015 Jul 13.

1] Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany. [2] Department of Pathology, University Hospital Cologne, 50937 Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14664DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861069PMC
August 2015

Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.

Clin Cancer Res 2015 May 11;21(9):1989-94. Epub 2014 Dec 11.

Department of Translational Genomics and Pathology, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0854DOI Listing
May 2015

CD74-NRG1 fusions in lung adenocarcinoma.

Cancer Discov 2014 Apr 27;4(4):415-22. Epub 2014 Jan 27.

1Department of Translational Genomics; 2Department I of Internal Medicine; 3Laboratory of Translational Cancer Genomics; 4Network Genomic Medicine, University Hospital Cologne, Center of Integrated Oncology Cologne-Bonn; 5Center for Molecular Medicine Cologne (CMMC); 6Cologne Center for Genomics (CCG); 7Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); 8Department of Pathology, University Hospital Medical Center, University of Cologne; 9Blackfield AG; 10Max Planck Institute for Neurological Research; 11Thoracic Surgery, Lungenklinik Merheim, Kliniken der Stadt Köln gGmbH; 12Institute of Human Genetics, Cologne; 13Computational Molecular Biology Department, Max Planck Institute for Molecular Genetics, Berlin; 14Department of Prostate Cancer Research, Institute of Pathology; 15Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn; 16Institute of Pathology; 17Department of Internal Medicine II, Jena University Hospital, Friedrich-Schiller-University, Jena; 18Institute for Pathology Bad Berka, Bad Berka, Germany;19Division of Molecular Oncology, Aichi Cancer Center Research Institute; 20Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan; Departments of 21Surgery and22Pathology, St. Vincent's Hospital; 23Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;24Department of Pathology, 25CHU Grenoble Institut National de la Santé et de la Recherche Medicale (INSERM) U823, Institute Albert Bonniot, Grenoble-Alpes University, Grenoble, France; 26Laboratory of Oncology IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo; 27Laboratory for Molecular Medicine and Biotechnology, University Campus Bio-Medico, Rome, Italy; 28Center for the Biology of Disease, VIB, Leuven; and 29Oncology Discovery, Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0633DOI Listing
April 2014

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

Cancer Discov 2014 Feb 3;4(2):246-57. Epub 2013 Dec 3.

1Department of Translational Genomics, University of Cologne; 2Max-Planck-Institute for Neurological Research; Institutes of 3Pathology and 4Virology, University of Cologne;5Department I of Internal Medicine and Center for Integrated Oncology, University Hospital of Cologne; 6Blackfield AG, Cologne; 7Technical University Dortmund, Dortmund, Germany; 8Medical Oncology and 9Institute of Pathology, Cantonal Hospital, Luzern; 10Novartis Pharma AG, Basel, Switzerland; and 11Division of Natural Products Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-13-0323DOI Listing
February 2014

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Nat Genet 2012 Oct 2;44(10):1104-10. Epub 2012 Sep 2.

Department of Translational Genomics, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915822PMC
October 2012

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.

Int J Cancer 2011 Apr;128(8):1813-21

International Agency for Research on Cancer, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.25512DOI Listing
April 2011

Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines.

Breast Cancer Res Treat 2011 Jan 11;125(1):35-42. Epub 2010 Mar 11.

Molecular Carcinogenesis Group, International Agency for Research on Cancer, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-010-0819-xDOI Listing
January 2011

p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.

Cancer Lett 2011 Jan 10;300(2):215-24. Epub 2010 Nov 10.

International Agency for Research on Cancer, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2010.10.008DOI Listing
January 2011